Trial
NCT04150029
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Acute Myeloid Leukemia
Intervention
MBG453
Why stopped
Novartis made a decision to early terminate the sabatolimab clinical development program, including the CMBG453C12201 trial, following the negative results from other 2 trials.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-13